Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs. The Company’s current assets consist of €30,196 thousand in cash and cash equivalents, compared to €3,386 thousand in the same period of 2022, which is 85% higher than last year. This is mainly driven by the progressive shift from early to late-stage development of several product candidates. In October 2023, AltaThera Pharmaceutical